Recon: Biogen gets FDA priority review for aducanumab; Japan signs deals for AstraZeneca, Novavax COVID-19 vaccines

• FDA grants expedited review to Biogen's Alzheimer's drug (Reuters) (Bloomberg) (STAT)
• Trump Signs Executive Order to Boost US Production of Essential Medicine (WSJ) (STAT)
• Teva CEO Has Doubts About Making Generic-Drug Ingredients in the U.S. (Barron’s)
• Moderna Backtracks to Open Covid Vaccine Trial to Those With HIV (Bloomberg)
• Pfizer to make Gilead's COVID-19 treatment remdesivir (Reuters) (Press)
• AbbVie pays $24m to settle lawsuit over using ‘nurse ambassadors’ to boost Humira sales (STAT)
• 'All Bark And No Bite': Trump Holds Prescription Drug-Pricing Order In Search Of Deal (NPR)
• Democrats try to force Trump to boost medical supplies production (The Hill)
• Congress Fails To Reach Agreement On New COVID-19 Relief Bill (NPR)

• Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines (Reuters)
• Swiss government signs agreement with Moderna for COVID-19 vaccine (Reuters)
• UK's Hikma making Gilead's COVID-19 drug remdesivir to increase supply (Reuters)
• South Korea approves human trial for Genexine's coronavirus treatment drug (Reuters)
• Italy becomes first country to require pharma to disclose public funding for R&D costs (STAT)
• In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer (Endpoints) (Press)
• No English Funding For Lymphoma Drugs Ledaga and Poteligeo (Pink Sheet)
• WHO asks the US to reconsider withdrawing from international group (CNBC)

• Prices For COVID-19 Vaccines Are Starting To Come Into Focus (NPR)
• Gates Foundation invests in $3 COVID-19 vaccine for poorer countries (The Hill)
• Pressure mounts on FDA chief to stick with science for Covid-19 vaccine approvals (STAT) (Endpoints)
• Preapproval Promotion? US FDA Commissioner Touts ‘Lifesaving’ Investigational Plasma For COVID-19 (Pink Sheet)
• U.S. surpasses 160,000 coronavirus deaths as school openings near (Reuters)
• Ohio Gov. Mike DeWine Tests Positive, Then Negative For COVID-19 (NPR)
• University of Washington forecasts 300,000 U.S. COVID-19 deaths (Reuters)
• MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures (PharmaJapan)
• Even Asymptomatic People Carry the Coronavirus in High Amounts (NYTimes)
• Hungary ties up close to 5 million vaccine dosages in EU scheme: PM Orban (Reuters)
• Multiple sclerosis drug to be studied for COVID-19 treatment (NBC)
• The Coronavirus Is New, but Your Immune System Might Still Recognize It (NYTimes)
• Coronavirus (COVID-19) Update: Daily Roundup August 6, 2020 (FDA)

• AbbVie abandons a pioneering CRISPR R&D alliance with Editas as Brent Saunders' deal is cast out (Endpoints) (BioPharmaDive)
• Biohaven adds nearly $1B in Nurtec deals with Royalty Pharma, Sixth Street (Endpoints)
• Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps (NEJM)
• Vizient Looks to Biosimilars to Help Contain COVID-19 Drug Price Inflation (Big Molecule Watch)
• Hospital president wrote opinion piece critical of drug pricing efforts, but didn’t disclose role on Moderna board (STAT)
• Perceptive fields SPAC #3 as another group of biotechs scoops up $364M in latest Nasdaq romp (Endpoints)
• RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed cancer med (Endpoints)
• Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer (Press)

• FDA confirms Samsung’s Galaxy Watch 3 is cleared for EKG, just like the Apple Watch (The Verge)
• NIH launches imaging AI collaboration for COVID-19 and beyond (Fierce)
• J&J’s Ethicon touts surgical stapler study (MassDevice)
• Endologix wins CE Mark for Alto abdominal stent graft system (MassDevice)
• Insulet up on Street-beating Q2, raised guidance (MassDevice)
• InspireMD posts Street-beating Q2 results (MassDevice)

• Most Courts Follow 1st Circ. Generic-Delay Ruling's Standard (Law360)
• DEA Beats Discovery Subpoenas In Opioid MDL Bellwether (Law360)
• Pharmacies Can't Dodge Ohio Opioid MDL's 2021 Bellwether (Law360)
• Paul Hastings Nabs Sidley Pair For FDA Regulatory Group (Law360)
• J&J Stung by New Jersey Court Ruling Reviving Talc Cancer Claims (Bloomberg)
• Statement on the classification of insulin products and duration of action: Notice to stakeholders (Health Canada)